Related Experiment Video
Updated: May 21, 2026
07:52
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Neuregulin-1 Mitigates Kidney Injury in Humanized Sickle Cell Mice.
William K Agbozo1,2,3, Wesley Solomon1, Isaac Joe Erskine4
1Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA.
Summary
Neuregulin-1 (NRG-1) shows promise in protecting against sickle cell disease (SCD) related kidney damage. This therapy reduced harmful mediators and improved kidney health in a mouse model, offering new hope for SCD patients.
Area of Science:
- Nephrology
- Hematology
- Molecular Medicine
Background:
- Sickle cell disease (SCD) involves chronic hemolysis and inflammation, leading to progressive kidney injury and high mortality.
- Current therapeutic options for SCD-related kidney complications are limited.
- Neuregulin-1 (NRG-1) is a growth factor with known cytoprotective, anti-inflammatory, and antioxidant properties.
Purpose of the Study:
- To investigate the therapeutic potential of Neuregulin-1 (NRG-1) in mitigating kidney injury in a sickle cell disease (SCD) mouse model.
- To determine if NRG-1 reduces hemolytic and inflammatory mediators while enhancing renal protective and repair factors in SCD.
- To elucidate the mechanisms by which NRG-1 impacts kidney pathology in SCD.
Main Methods:
- Utilized Townes humanized sickle cell (HbSS) mice to model SCD.
- Administered NRG-1 treatment to assess its effects on kidney injury markers.
- Measured plasma and urinary biomarkers, including heme, lactate dehydrogenase, cytokines, cystatin C, NGAL, clusterin, and EGF.
- Evaluated renal histopathology, focusing on iron deposition, glomerular congestion, and sclerosis.
- Assessed heme oxygenase-1 (HO-1) expression in kidney tissues.
Main Results:
- NRG-1 treatment significantly reduced plasma heme, lactate dehydrogenase, and pro-inflammatory cytokine levels.
- Increased proportion of circulating fetal hemoglobin-containing red blood cells (F-cells) was observed.
- Mitigated elevations in urinary cystatin C and neutrophil gelatinase-associated lipocalin (NGAL).
- Improved renal histopathology, characterized by reduced iron deposition, glomerular congestion, and sclerosis.
- Enhanced heme oxygenase-1 (HO-1) expression in HbSS kidneys and increased urinary clusterin and epidermal growth factor (EGF).
Conclusions:
- NRG-1 demonstrates significant renoprotective effects in a sickle cell disease mouse model.
- The therapeutic benefits of NRG-1 are linked to the reduction of hemolytic and inflammatory mediators and enhancement of renal repair pathways.
- These findings provide mechanistic insights supporting NRG-1 as a potential therapeutic agent for kidney injury in SCD.
